Font Size




Menu Style

AVG Home

Future Events

The 5th isirv-AVG Conference entitled ‘Prevention and Treatment of RVIs: Antivirals, Traditional Therapies  and Host-Directed Interventions’ will take place at the Regal East Asia Hotel, Shanghai, China, 14-16 June 2017 – Registration and Abstract Submission is now Open

The Yu Garden

Recent Event

GISAID-ISIRV-WHO Workshop on ‘Genetic Analyses of Influenza Viruses’,  29th August 2016, Northwestern University, Chicago

GISAID in collaboration with Northwestern University and the International Society for Influenza and Other Respiratory Virus Diseases (isirv) organised a training workshop on Genetic Analyses of Influenza Viruses at Northwestern University on 29 August 2016 in Chicago, following the IX Options for the Control of Influenza Conference, 24-28 August.

The purpose of the training workshop was to enable laboratories to contribute to and benefit from the extensive genetic and related data on influenza viruses, in relation to understanding the epidemiology of influenza, the evolution of the viruses and the emergence and spread of novel genetic and antigenic variants. Participants were instructed in the use of GISAID’s new EpiFlu™ 2.0 database, its novel features and advanced analysis tools for the identification (and display on phylogenetic trees) and interpretation (using FluSurver) of mutations underlying the evolution and antigenic variation of human and animal influenza viruses. Enhanced capacity to analyse and understand the relationships among influenza viruses is aimed at stimulating increased interaction between institutions involved in human and animal influenza surveillance and research. The programme included a combination of brief lectures, demonstrations and hands-on training – seattached.

Group photo Bioinformatics Workshop Aug 2016

AVG Overview

The isirv Antiviral Group (isirv-AVG) was established as a special interest group of isirv at the time of merger in April 2011 of the former Neuraminidase Inhibitor Susceptibility Network (NISN) with isirv.

Its specific objectives are to promote understanding of the clinical use of antivirals against respiratory viruses, collate and provide up to date information on the emergence of antiviral resistance, and communicate expert commentary on preclinical and clinical development of potential novel/new antivirals in this area. Read More

AVG Meetings

Training Workshop on Genetic Analyses of Influenza Viruses, Hong Kong Polytechnic University, 21-22 November 2015

 GISAID-isirv Workshop-2 

The 2-day training workshop on Genetic Analyses of Influenza Viruses, organised by isirv in conjunction with the GISAID Initiative, the WHO Global Influenza Surveillance and Response System and the Hong Kong Polytechnic University, was held at the Polytechnic University on 21-22 November 2015. The 33 trainees, from 24 countries, received instruction in the use of GISAID’s EpiFlu™ database and its new EpiFlu™ 2.0 platform, with its novel features and advanced analysis tools for the identification and interpretation of mutations underlying the evolution and antigenic variation of human and animal influenza viruses. Participants received financial support from the WHO, its Western Pacific regional office and isirv.

A summary report can be found here.

Texas banner 890

4th isirv Antiviral Group Conference, 2- 4 June 2015

The University of Texas at Austin, Texas, USA

The 4th AVG Conference held at the University of Texas on 2-4 June attracted a capacity audience of 200 registered participants. Against a backdrop of resistance to the licensed antivirals against influenza viruses and the lack of effective interventions against other respiratory viruses, the 3-day programme focused on the discovery and development of inhibitors of novel virus targets and key host cell factors. In relation to the development of monoclonal antibodies as therapeutics, the potential implications of antibody-dependent enhancement of disease were also addressed. The ten sessions covered the whole gamut of steps from structural and molecular biology to clinical studies, and included consideration of clinical trial endpoints and regulatory issues.

The inaugural ‘live’ twitter coverage was a very successful innovation. More than 160 tweets under the hashtag “#isirvAVG2015” were posted and the number of twitter “followers” of isirv-AVG doubled. The social media coverage not only showcased the speakers but also reached out to the wider scientific community. The "Meeting Report" can be foundheretwitter

NGS Meeting 2021 May 2015 - group photo 2

The Workshop on Next Generation Sequencing (NGS) of Viruses, organised by the isirv-AVG in conjunction with GISAID and the PREDEMICS Consortium, held at the Institut Pasteur, Paris on 20-21 May 2015 attracted 117 registered participants. The 2-day expert workshop covered various aspects of current sequencing technologies, data processing and analysis of data for a variety of RNA viruses, with a particular focus on quality and interpretation of results and the significance and use of NGS data for public and animal health.

A summary can be found here

Antiviral News

Prospective surveillance of antiviral resistance in hospitalized infants less than 12 months of age with A(H3N2) influenza infection and treated with oseltamivir

Surveillance of hospitalised infants undergoing oseltamivir therapy during the 2008-2009 and 2011-2012 influenza seasons in Germany revealed that a high proportion of subjects (73%) infected with influenza A(H3N2) viruses continue to shed virus at the end of the five days treatment regimen. Two out of 37 subjects were found to shed resistant viruses harbouring the R292K neuraminidase mutation…read more


An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses

An investigational M2-V27A inhibitor, spiroadamantane amine was found to inhibits the replication of amantadine-sensitive and –resistant (V27A) influenza A viruses in vitro and treatment with this molecule confer protection in mice infected with influenza more

The PA endonuclease inhibitor RO-7 protects mice from lethal challenge with influenza A or B viruses

In a mouse model of influenza A and B infection, the treatment with PA endonuclease inhibitor, RO-7 was found to decrease infection associated mortality, pulmonary viral titre and lung pathology. No viral resistance to RO-7 was detected and viruses remained susceptible to the drug…read more 

Influenza antivirals currently in late-phase clinical trial

A review focusing on investigational influenza antivirals, such as host cell targeting molecules (Nitazoxanide, DAS181), viral polymerase inhibitors (T-705, JNJ63623872, S-033188) and monoclonal antibodies in late-phase clinical trial…read more

Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol

This unique binding mode compared with the small-molecule inhibitors of other class I fusion proteins enhances our understanding of how small molecules can function as fusion inhibitors and guides the de- velopment of broad-spectrum therapeutics against influenza more

Read More News

Visit us on:  facebook  twitter

Quick links:

Contact AVG:


Login to isirv members database

Click here for database login